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Abstract
Background: Hypertrophic Cardiomyopathy (HCM) is a genetically heterogeneous disease. One specific mutation in
the MYBPC3 gene is highly prevalent in center east of France giving an opportunity to define the clinical profile of
this specific mutation.
Methods: HCM probands were screened for mutation in the MYH7, MYBPC3, TNNT2 and TNNI3 genes. Carriers of
the MYBPC3 IVS20-2A>G mutation were genotyped with 8 microsatellites flanking this gene. The age of this
MYBPC3 mutation was inferred with the software ESTIAGE. The age at first symptom, diagnosis, first complication,
first severe complication and the rate of sudden death were compared between carriers of the IVS20-2 mutation
(group A) and carriers of all other mutations (group B) using time to event curves and log rank test.
Results: Out of 107 HCM probands, 45 had a single heterozygous mutation in one of the 4 tested sarcomeric
genes including 9 patients with the MYBPC3 IVS20-2A>G mutation. The IVS20-2 mutation in these 9 patients and
their 25 mutation carrier relatives was embedded in a common haplotype defined after genotyping 4 polymorphic
markers on each side of the MYBPC3 gene. This result supports the hypothesis of a common ancestor. Furthermore,
we evaluated that the mutation occurred about 47 generations ago, approximately at the 10th century.
We then compared the clinical profile of the IVS20-2 mutation carriers (group A) and the carriers of all other
mutations (group B). Age at onset of symptoms was similar in the 34 group A cases and the 73 group B cases but
group A cases were diagnosed on average 15 years later (log rank test p = 0.022). Age of first complication and first
severe complication was delayed in group A vs group B cases but the prevalence of sudden death and age at
death was similar in both groups.
Conclusion: A founder mutation arising at about the 10th century in the MYBPC3 gene accounts for 8.4% of all
HCM in center east France and results in a cardiomyopathy starting late and evolving slowly but with an apparent
risk of sudden death similar to other sarcomeric mutations.
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Background
Hypertrophic cardiomyopathy (HCM) is a frequent ge-
netic disorder with an autosomal dominant inheritance.
The prevalence of HCM is estimated at 1 in 500 in the
general population [1]. It is likely that the prevalence of
carriers with one of the genetic mutations that predis-
pose to HCM is much higher, since the penetrance of
the disease is variable and many asymptomatic carriers
remain undiagnosed [2,3]. Sudden death can be the first
symptom of the disease especially in young people where
HCM is estimated an important underlying cause [4,5].
On the other hand, a proportion of carriers are asymp-
tomatic and some HCM patients can have a normal life
expectancy [6,7]. Sixty percent of HCM are caused by
mutations in sarcomere genes. So far, defects in at least
13 different genes which encode a protein component of
the sarcomere have been identified and more than 1000
different mutations within these genes were found [8-10].
Defects in the beta-myosin heavy chain (MYH7) and
myosin-binding protein C (MYBPC3) genes are the most
frequent causes for HCM. Defects in other genes like tro-
ponin T (TNNT2), troponin I (TNNI3), alpha-tropomy-
osin (TPM1), regulatory and essential myosin light chain
(MYL2, MYL3), alpha-actin (ACTC1), titin (TTN) and
alpha-myosin heavy chain (MYH6) are less frequent
causes for HCM [8-10].
A great variation in age at onset and severity of fea-
tures of HCM has been observed between HCM patients
with sarcomere gene defects. Elucidation of phenotype/
genotype correlation of HCM is of special interest be-
cause this may allow risk stratification according to
genetic defects. The study of genotype/phenotype corre-
lation has been hampered because of the many different
mutations and low frequency of each mutation. It is also
believed that there are genetic modifier factors that ei-
ther compensate or aggravate the impact of the causal
mutation [11]. In center east of France, 9 families with
more than 30 carriers of the same genetic mutation
(GenBank: NM_000256.3 c.1928-2A>G or IVS20-2A>G)
in the MYBPC3 gene are currently followed at the
Groupe Hospitalier Est in Lyon. In this report, we
demonstrated that this was a founder mutation and we
further detailed the clinical profile resulting from this
mutation with delayed age at diagnosis despite early
symptoms, a slow progression toward complications but
a risk of sudden death similar to carriers of other sarco-
meric mutations.
Methods
Ethics statement
Before proceeding to blood drawing, informed consent
was signed by the patient or by parents. The informed
consent was requested for diagnosis and for research pur-
poses. Only blood samples which were obtained with an
agreement for both diagnosis and research were used in
this study. This procedure complies with the current laws
in France (Loi Biomédecine 2004) and the last version
of the Declaration of Helsinki (The World Medical
Association, 2008).
Study population
The diagnosis of Hypertrophic Cardiomyopathy (HCM)
was established according to international criteria [12].
Patients diagnosed with hypertrophic cardiomyopathy,
whatever their age, were proposed to have a visit with a
geneticist in order to obtain family medical history and
to propose a genetic screening of the 4 following sarco-
meric genes: MYBPC3, MYH7, TNNT2 and TNNI3. The
pathogenicity of variants was inferred from several cri-
teria: conservation of the amino-acid, location in a pro-
tein domain, absence from controls (200 healthy ethnic
matched controls, 1 000 genomes and the Exome Var-
iant Server), published mutation. If a mutation was
found, it was systematically confirmed by a second sam-
ple and relatives were systematically proposed to be
tested for their status of carrier or non-carrier. In any
case, patients received genetic counseling.
We selected all persons with a mutation in one of the
following genes MYBPC3, MYH7, TNNT2 or TNNI3
(HCM patients and mutation carrier relatives whether
they were symptomatic or not). Among 107 HCM
patients, a mutation was found in 53 cases. Eight HCM
cases were excluded because they were double (7 cases)
or triple (1 case) heterozygotes. Among the 45 single het-
erozygote HCM cases, 9 had the same MYBPC3 mutation
(IVS20-2A>G). A mutation screening was proposed to
relatives irrelevant to age, clinical status and mutation.
Mutation carriers were classified into one group of 34
carriers of the MYBPC3 IVS20-2A>G mutation (group
A) and 73 carriers of any other single mutation in the
MYBPC3,MYH7,TNNT2 or TNNI3 genes (group B). This
latter group included 15 MYBPC3 probands (other than
the IVS20-2A>G mutation), 16 MYH7, 2 TNNT2 and 3
TNNI3 probands (Figure 1).
Genotyping
The MYBPC3 gene is located on the short arm of
chromosome 11 close to the centromere from nt 47 352
957 to nt 47 374 253 according to Ensembl database.
Four polymorphic markers on each side of the MYBPC3
gene were selected: D11S1763, D11S986, D11S4137
and D11S1344 on the telomeric side and D11S1784,
D11S1326, D11S4165 and D11S1765 on the centro-
meric side. These polymorphic markers are at geno-
mic position 42 861 500 nucleotides (nt), 44 722 300
nt, 45 601 500 nt and 46 167 00 nt on the telomeric
side and 48 022 900 nt, 49 324 500 nt, 50 138 000 nt
and 66 778 544 nt on the centromeric side of the
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MYBPC3 gene, respectively. All IVS20-2 MYBPC3 muta-
tion carriers were genotyped. In addition, the DNAs of 50
controls of the same European origin were genotyped at
these 8 polymorphic markers to evaluate the distribution
of alleles in the general European population. Genotyping
was performed with the universal fluorescent labeling
method [13]. In brief, a tag sequence (50 – GGTGGC
GACTCCTGGAG – 30) was added to the 50-end of the
forward primer. A fluorescent-labeled primer (FAM –
GGTGGCGACTCCTGGAG – 30) was added to the PCR
reaction. PCR reaction were obtained using 10 ng of gen-
omic DNA, 10 mM Tris–HCl (pH 8.8), 50 mM KCl,
1.5 mM MgCl2, 100 μM deoxynucleotide triphosphate, 5
pmol of each tagged forward primer and FAM-labeled re-
porter primer, 10 pmol of reverse primer and 0.5 units of
Taq polymerase in a total volume of 20 μl. Cycling condi-
tions were 94°C for 60 sec, 60°C for 60 sec, and 72°C
for 60 sec in a Robotcycler (Stratagene, Netherland). PCR
products were electrophoresed in an ABI 3100 system
(Applied Biosystems, Foster city, CA), and the data were
analyzed using GeneScan Analysis Software version 2.1
(Applied Biosystems).
Haplotype reconstruction and search for a common
ancestor
Haplotypes were reconstructed starting with the family
with the largest number of mutation carriers. Allele fre-
quency was estimated on a group of 50 controls. The
Genethon and the deCode genetic maps were used to
infer the position of the 8 polymorphic markers.
Recombination fractions between the different markers
and the MYBPC3 gene were then computed from gen-
etic distances using Kosambi mapping function assum-
ing that the correlation between genetic and physical
distances between the two closest markers to MYBPC3
was constant in this interval. We then used the ESTI-
AGE program [14] to estimate the age of the most re-
cent ancestor of this mutation. A mutation rate of 10-4
per individual per generation and a stepwise mutation
model was assumed at the polymorphic markers.
Patients were assumed to carry the ancestral haplotype
on each side of the mutation up to the first marker
where they do not show an allele similar to the ancestral
allele at this locus.
Design and setting of clinical profiling
We performed a retrospective cohort study. Information
was retrieved from the medical records. Family histories
were ascertained during genetic consultations. In addi-
tion for this study, all participants were contacted by
telephone and administered a semi-structured question-
naire. With consent of the participants, their cardiologists
were requested to fill in a semi-structured questionnaire
asking for an update about follow-up and the results
of clinical tests like echocardiograms and electrocardio-
grams. Participants and their cardiologists were asked to
send copies of reports on medical examinations, electro-
cardiograms (at rest and ambulatory), and echocardio-
grams. About half of the participants are jointly followed
by their local cardiologist and our center. Thus, we could
also get directly information from our center. Family his-
tories were evaluated for the occurrence of sudden death.
Statistical data analysis
We used SPSS version 15.0 to analyze the data. Compari-
sons were made with Student’s t-test and Chi Square. For
time free from clinical event analysis, we created Kaplan-
Meier curves and comparisons of time free from clinical
event curves between groups were performed with a log
rank test. To evaluate the prevalence of sudden death, we
recorded all sudden death in each family among all family
members reported during family history registering.
Results
Study population
Carriers of the MYBPC3 IVS20-2A>G mutation were
assigned as group A and the carriers of one of the other
mutations in the examined sarcomere genes MYBPC3,
MYH7, TNNT2 and TNNI3, were group B cases. Altoge-
ther, 107 subjects from 45 different families were included.
There were 34 MYBPC3 IVS20-2A>G carriers (group A)
from 9 apparently unrelated families and 73 all other mu-
tations carriers from 36 families (group B) (Figure 1). The
mutations of group B cases are presented in Table 1. All
Figure 1 Scheme summarizing the sorting process of HCM cases.
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but 2 of these 29 different mutations were already re-
ported by Millat et al. (2010) [15]. One of these 2 mu-
tations is the mutation MYH7 p.Arg453His which has
already been reported by Yu et al. [16] and the other is the
in-frame deletion of 4 highly conserved amino-acids
(p.1101_1104delGSQL) at the beginning of the myosin
tail. Three mutations in MYH7 (p.Thr177Ile, p.Asn696Ser
and p.Ile1927Phe) were previously reported by Millat et al.
(2010) [15] in HCM patients carrying also other muta-
tions. In the current report, only individuals carrying a
single heterozygous mutation were included. All 3 amino-
acids are highly conserved and predicted as disease
causing and deleterious (Mutation Taster and SIFT). In
addition, the MYH7 p.Asn696Ser mutation was already
reported by Jaaskelainen et al. [17]. None of these 5 muta-
tions were found in the SNP databases and in 200 ethni-
cally matched controls.
There was no difference in gender between group A
and B mutation carriers (p = 0.13). The same percentage
of group A and group B cases were diagnosed with
HCM (62%, n = 21) and (67%, n = 49) (p = 0.59), respec-
tively (Table 2). In total 23 (68%) group A cases and 49
(67%) group B cases reported symptoms (p = 0.96), in-
cluding dyspnea, fatigue, palpitations, syncope (malaise
and/or loss of consciousness) and thoracic pain (specific
and non-specific) or were said to have a heart murmur.
The average age at last visit was 47 years in group A and
39 years in group B (p = 0.045).
Founder effect
All IVS20-2 mutation carriers were genotyped for markers
D11S1763, D11S986, D11S4137 and D11S1344 on the
telomeric side of MYBPC3 and D11S1784, D11S1326,
D11S4165 and D11S1765 on the centromeric side. Be-
cause MYBPC3 is located close to the centromere, we
selected the most distal polymorphic marker (D11S1765)
on the other side of the centromere (hence in the long
arm of chromosome 11) at a physical distance of more
than 13 million nucleotides. Physical and genetic map
positions are provided on Table 3. Physical positions are
Table 1 Mutation description of group B cases (All other
mutations)
Gene Mutation Number of carriers
MYBPC3 p.Tyr79X 5 (1)
MYBPC3 p.Arg272Cys 1 (1)
MYBPC3 IVS7+5G>A 6 (3)
MYBPC3 p.Phe305fs 1 (1)
MYBPC3 IVS12-2A>G 1 (1)
MYBPC3 IVS13+1G>A 1 (1)
MYBPC3 p.Arg495Gly 2 (1)
MYBPC3 p.Ala701Thr 1 (1)
MYBPC3 p.Arg943X 2 (2)
MYBPC3 p.Gln969X 2 (1)
MYBPC3 p.Ile1131Thr 1 (1)
MYBPC3 p.Cys1244X 5 (1)
MYBPC3 p.Tyr1251X 1 (1)
MYH7 p.Thr177Ile 5 (1)
MYH7 p.Arg403Gln 1 (1)
MYH7 p.Val411Ile 3 (1)
MYH7 p.Arg453His 1 (1)
MYH7 p.Val606Met 6 (2)
MYH7 p.Asn696Ser 1 (1)
MYH7 p.Arg719Trp 1 (1)
MYH7 p.Arg719Gln 3 (1)
MYH7 p.Val878Gly 3 (1)
MYH7 p.1101_1104delGSQL 3 (1)
MYH7 p.Arg1420Trp 4 (2)
MYH7 p.Ile1927Phe 3 (1)
TNNT2 p.Ala157Ser 1 (1)
TNNT2 p.Arg278Cys 2 (2)
TNNI3 p.Arg136Gln 1 (1)
TNNI3 p.Lys183Asn 6 (2)
Bold letters for mutations not reported by Millat et al. 2010 [15] or mutations
reported in double heterozygotes ou compound heterozygotes by Millat et al.
2010 [15]. Numbers in parenthesis: number of families.
Table 2 Demographic data on the groups A (MYBPC3
IVS20-2A>G) and B (all other mutations carriers)
Group A Group B
Subjects (n) 34 73
Families (n) 9 36
Women (n) 23 (67.6%) 38 (52.1%)
Patients with HCM (n) 21 (61.8%) 49 (67.1%)
Symptomatic carriers (n) 23 (67.6%) 49 (67.1%)
Average age at last visit (year) 47.28* 39.07
*: p < 0.05.
Table 3 Physical and genetic positions of the polymorphic
markers flanking the MYBPC3 gene used in this study
AFM name D name Physical position
(nucleotides)
Genetic
position (cM)
AFM162xg1 D11S1763 42 861 500 4.92
AFM255ye1 D11S986 44 722 300 2.06
AFMb036ya9 D11S4137 45 601 500 0.48
AFM298vc9 D11S1344 46 167 000 0.14
Mutation 47 361 363 0.00
AFMa139yb9 D11S1784 48 022 900 0.16
AFM255zg1 D11S1326 49 324 500 0.17
AFMb333ye1 D11S4165 50 138 000 0.23
AFM165zc3 D11S1765 60 778 500 2.28
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referring to chromosomal positions whereas genetic po-
sitions are given relative to the MYBPC3 gene. The
complete haplotype of the mutation could be inferred in 7
of the 9 families (F01-F05, F07 and F08) and in 2 families
the allele associated with the IVS20-2 could not be deter-
mined at a single polymorphic marker (families F06 and
F09) (Table 4) because mutation carriers had the same 2
alleles. On the centromeric side, all IVS20-2 mutation
carriers had the same allele at the 3 closest markers
to MYBPC3: 160 (D11S1784), 268 (D11S1326), 237
(D11S4165) (from the MYBPC3 gene toward the centro-
mere) but 5 of the 9 possible alleles were found on the
most distal marker (D11S1765). On the telomeric side, all
families had the same allele only at the closest poly-
morphic marker to MYBPC3: 293 (D11S1344). The next
tested polymorphic marker away from the MYBPC3 gene
was D11S4137. Families F01 to F05 had allele 298, while
families F07 to F09 had the allele 284. Family F06 was too
small to determine the allele associated with the IVS20-2
mutation. The allele could be 284 or 298 (Table 4). For
the most distant markers on the telomeric side (D11S986
and D11S1763), 6 out of 13 possible alleles and 4 out of 5
possible alleles were found, respectively. These data dem-
onstrate that the haplotype carrying the IVS20-2MYBPC3
mutation was the same in all 9 families lending support to
the hypothesis of a founder mutation. Furthermore, it sug-
gested a phylogenic tree between IVS20-2 families with 2
main branches one carrying the 284 allele and the other
the 298 allele at marker D11S4137. Families F03 and F04
shared the same haplotype on 7 of the 8 analyzed poly-
morphic markers, while families F05 and F06 might also
share a common haplotype on 7 of the 8 markers. The ap-
proximate time of occurrence of this mutation was in-
ferred by the ESTIAGE software taking into account the
genetic distance between polymorphic markers and the
prevalence of alleles associated to IVS20-2 mutations. The
estimation was that the mutation occurred 47 generations
(CI 95%, 27 – 65) ago. With an average generation every
20–25 years, the mutation appeared approximately 10
centuries ago (time range from the 4th to the 15th century).
Since IVS20-2 mutations carriers of these 9 families were
actually descendants of a common ancestor, they all car-
ried the same haplotype on the chromosomal region adja-
cent to the IVS20-2 MYBPC3 mutation. A genetically
homogenous population of HCM patients provides an op-
portunity to evaluate the clinical profile of the cardiomy-
opathy caused by this mutation.
Diagnosis time and symptoms
The thickening of the ventricular septum to 13 mm was
reached on average 15 years later in life in group A than
in group B (Figure 2) log rank test p = 0.022. This figure
is interesting for 2 points that need to be detailed. First,
it clearly shows that the delay in the appearance of
hypertrophy between groups A and B was constant du-
ring life span since the 2 curves are parallel. Second, it is
also obvious for group A cases as well as for group B
that the disease penetrance increased at a regular pace
during life span since the 2 curves are nearly straight. By
contrast, the age at time of first symptoms was similar
in cases of group A and B (Log rank test p = 0.226),
(Figure 3). The frequency and nature of first symptoms as
fatigue, palpitations or thoracic pain was similar between
group A and B although dyspnea was reported slightly
more frequently as a first symptom in group B. Among
group A cases, there was a slight excess of patients
reporting to be diagnosed previously with a murmur or
Table 4 Haplotypes associated with the IVS20-2 mutation
in the 9 families (F01 to F09)
F01 F02 F03 F04 F05 F06 F07 F08 F09
D11S1763 201 199 201 201 201 201 203 199 197
D11S986 180 178 176 176 174 174 152 152 170/174
D11S4137 298 298 298 298 298 298/284 284 284 284
D11S1344 293 293 293 293 293 293 293 293 293
MYBPC3 M M M M M M M M M
D11S1784 160 160 160 160 160 160 160 160 160
D11S1326 268 268 268 268 268 268 268 268 268
D11S4165 237 237 237 237 237 237 237 237 237
D11S1765 262 262 260 249 249 259 259 259 253
M: mutation.
Figure 2 Age at diagnosis of hypertrophic cardiomyopathy.
Time free from diagnosis curve. Red graph: group A cases
(MYBPC3 IVS20-2A>G mutation carriers); green graph: group B
cases (all other mutation carriers). Log rank test p = 0.022.
Teirlinck et al. BMC Medical Genetics 2012, 13:105 Page 5 of 9
http://www.biomedcentral.com/1471-2350/13/105
to have suffered syncope. Interestingly, in group B, first
symptom and diagnosis of HCM occurred almost at the
same time (Figure 3) whereas diagnosis occurred several
years after onset of first symptoms in group A (Figure 2).
Complications
The following complications and therapeutic outcome
related to hypertrophic cardiomyopathy were registered:
external cardioversion, pacemaker implantation (both
events considered as moderate events), heart failure, in-
terventricular wall thinning (surgical or alcohol), defib-
rillator implantation, heart transplantation or cardiac
death (complications or therapeutic outcome considered
as severe). No subjects died between the time of molecu-
lar diagnosis and the end of the study. Five group A
cases (15%) and 19 group B cases (26%) had complica-
tions. Although the difference in overall complications
and therapeutic outcome was not significant (p = 0.19)
between groups A and B, there is an excess of implan-
tation of pacemakers and defibrillators, heart transplan-
tations and heart failure among the group B cases
(Table 5). Furthermore, group A cases were appro-
ximately 15 years older than group B cases when first
complications of HCM occurred (any moderate or se-
vere event) (Figure 4) (log rank test p = 0.047). When
comparing groups A and B about the age of occurrence
of severe complications or therapeutic outcome (heart
failure, interventricular wall thinning, defibrillator im-
plantation, heart transplantation, and cardiac death) the
curves were still separated but no longer statistically
different (log rank test p = 0.059). The approximate dif-
ference in age of severe complications or severe thera-
peutic outcome between groups A and B was only about
10 years (Figure 5). We examined the family history of
the participants to investigate if the prevalence of sud-
den death (SD) was higher in group A families than
group B families. In group A, SD was reported 14 times
in 9 families with 292 relatives whereas in group B, SD
was reported 25 times in 36 families with 837 relatives.
When we compared the prevalence of SD in group A
families (14/292 = 0.048) and group B families (25/837 =
0.030) the prevalence of SD was slightly higher in group
A then in group B but the relative risk was not statisti-
cally different: RR 1.6 95% CI 0.85-3.05. The mean age
at SD was statistically not different in group A vs group
B, 46.6 y. and 43.1 y., p = 0.59, respectively.
Discussion
This study clearly demonstrates that the MYBPC3
IVS20-2 mutation is a founder mutation in our cohort
and not a hot spot of mutation. Hot spots of mutation
are regions of DNA that are “fragile” and often mutated.
In this latter case, mutations appear independently at
different time and in different individuals. Although,
these individuals share the same mutation, they do not
share the same alleles in the adjacent DNA region. By
contrast, descendants of a mutation carrier will share
not only the mutation but also the alleles in the adjacent
genomic region. This is true for the closest DNA va-
riants to the mutation but less true for distant variants
because the probability that a mutation carrier has also
the founder allele at remote positions decreases with
genomic distance. This is due to the fact that the proba-
bility of the occurrence of a recombination increases
with the genomic distance between the mutation and
the variant. A founder mutation was already evidenced
in the MYBPC3 gene in other populations [18-21].
These founder mutations account for 24% (Netherland
[18]) to less than 15% (Germany [19], Finland [22], Japan
[20], Spain [21]) of HCM mutations. The IVS20-2
MYBPC3 mutation in our cohort accounts for 8.4% of
Figure 3 Age at first symptom. Time free from first symptom
curve. Red graph: group A cases (MYBPC3 IVS20-2A>G mutation
carriers); green graph: group B cases (all other mutation carriers).
Log rank test p = 0.226.
Table 5 complications in group A and B cases
Cardioversion Pacemaker Defibrillator Wall thinning Heart failure Heart transplantation
Group A (n) 2 (5.9%) 1 (2.9%) 1 (2.9%) 2 (5.9%) 2 (5.9%) 0
Group B (n) 5 (6.8%) 4 (5.5%) 8 (11.0%) 4 (5.5%) 11 (15.1%) 5 (6.8%)
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unselected HCM and 18% of HCM with at least a muta-
tion in the 4 tested sarcomeric genes. These founder
mutations are located in different gene regions but all pre-
dict a C-terminal truncated protein due to a premature ter-
mination codon: a nonsense as in Finland (Gln1061X) and
Turkey [19] or a frameshift as in Netherland (2373insG)
and Japan (c.11645delT, p.V592fs8X); or an altered spli-
cing as in Spain (IVS23+1G>A), in Germany [19] and in
France (IVS20-2A>G). In that respect, they are not differ-
ent from the other MYBPC3 mutations that lead in 80%
of the cases to premature termination of translation
either by introducing a stop codon, a frame-shift or an
altered splicing.
Since our patients not only carry the same MYBPC3
mutation but also the same variants within the MYBPC3
gene sequence and flanking DNA, the expression profile
of the mutation depends only on the other MYBPC3
gene copy and on distant genetic factors giving an op-
portunity to observe a specific clinical profile. Disease
signs in IVS20-2 MYBPC3 carriers appear at the same
age as in carriers of other sarcomeric mutations but the
diagnosis was delayed by approximately 15 years sugges-
ting that the electric and echocardiographic hypertrophy
is delayed in IVS20-2 carriers (group A). Interestingly, the
curves on first symptom and diagnosis age show that
there is no age threshold but rather a regular increase in
penetrance of the disease. A 15-year delay in the evolution
towards the first complications is also demonstrated when
IVS20-2 MYBCP3 mutation carriers are compared to
other mutation carriers. This relatively benign evolution
fades when focusing on severe complications and disap-
pears when concentrating on the risk of sudden death. By
contrast, Millat et al. (2010) [15] reported a higher sudden
death ratio in HCM probands with an identified mutation
compared to HCM probands with no identified mutation.
No systematic autopsy was performed in these sudden
death cases. Consequently, we cannot be certain that every
sudden death case is secondary to hypertrophic cardiomy-
opathy but there is no reason to believe that sudden death
cases of other origin are more prevalent in one group than
in the other. A previous study in the Netherlands showed
that MYBPC3 truncating mutations had mild effects in
the first three decades of life, while the phenotype later in
life is severe [23]. The relative high risk of sudden death
contrasting with a benign and delayed natural history was
also observed in the Japanese study [20] with 13% of sud-
den death over a mean follow-up of 9 years and in the
Spanish study [21] with 17 sudden deaths in 12 families. It
might seem surprising that mutations resulting in a high
risk of sudden death can nevertheless become a founder
mutation. Dominant mutations are generally responsible
for a negative pressure of selection and tend to dis-
appear after several generations because of this survival
decrease of mutation carriers. Founder mutations escape
Figure 4 Age at first complication or therapeutic outcome.
Time free from first complication curve. First complication or
therapeutic outcome: any of the following events: external
cardioversion, pacemaker implantation, interventricular wall thinning
(alcohol or surgery), defibrillator implantation, heart failure, heart
transplantation, cardiac death. Red graph = group A cases; green
graph = group B cases. Log rank test p = 0.047.
Figure 5 Age at first severe complication or severe therapeutic
outcome. Time free from first severe complication curve. Severe
complication or severe therapeutic outcome: any of the following
events: interventricular wall thinning (alcohol or surgery), defibrillator
implantation, heart failure, heart transplantation, cardiac death. Red
graph = group A; green graph = group B. Log rank test = 0.059.
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this pressure of selection and are transmitted along ge-
nerations. The reason for this exception is well demon-
strated in this report since the expression of the disease is
delayed beyond the reproductive age. Hence, when the
disease is responsible for complications, the patient has
already transmitted the mutation to his/her descendants.
When comparing the clinical profile of HCM depending
of the involved genes, one should keep in mind that the
percentage of founder mutation carriers might soften the
profile. For instances, in Finland or in The Netherlands
where about 24% of MYBPC3 mutation carriers have a
founder mutation, the mean MYBPC3 clinical profile can
only be mild. Does this hold true when founder mutation
carriers are removed? In particular, it would be interesting
to study separately MYBPC3 missense mutations that
could result in HCM clinical profile comparable to muta-
tions in theMYH7 gene.
Conclusion
The IVS20-2A>G mutation in the 9 families followed at
the department of cardiogenetics in Lyon, is a founder
mutation since mutation carriers also share the adjacent
genomic region. Carriers of the IVS20-2A>G mutation
in the MYBPC3 gene were diagnosed later in life than
carriers with other mutation in the MYBPC3, MHY7,
TNNT2 and TNNI3 genes, despite the fact that they
experienced first symptoms at the same age. The delay
in diagnosis in this particular group of patients is prob-
ably due to a delayed appearance of hypertrophy, leading
to later diagnosis. Accordingly, complications were ob-
served later in life in HCM patients with the IVS20-2
mutation than in HCM patients with other mutations.
Nevertheless, the IVS mutation was associated with the
same high rate of SD as carriers of other mutations.
Therefore, despite the late onset and the delayed evolu-
tion towards complications, our study shows that cardio-
logists should keep in mind a risk of SD in families with
the MYBPC3 IVS20-2A>G mutation.
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